HBVcccDNA定量检测在拉米夫定阻断乙肝病毒宫内感染中的应用价值

摘要

目的 分析HBVcccDNA应用于诊断HBV宫内感染的价值,评价拉米夫定阻断HBV宫内感染的效果.方法 选择2011年6月至2012年5月我院门诊及住院分娩的孕妇共60例,随机分为治疗组32例与对照组28例,孕妇均于孕28周、产前,产后24h与产后3个月采血,对HBVDNA、HBVcccDNA水平采用PCR方法进行检测,并收集结果,同时收集产时胎盘组织HBVcccDNA定量结果及宫内感染率,对两组数据进行分析.结果 治疗组孕妇在孕28周检测HBV-DNA、HBVcccDNA水平与对照组比较,差异无统计学意义(P＞0.05)；治疗组孕妇在产前,产后24h与产后3个月HBV-DNA、HBVcccDNA水平及产时胎盘组织HBVcccDNA水平与对照组相比明显不同,差异具有统计学意义(P＜0.05),其新生儿宫内感染率明显低于对照组(P＜0.05).结论 HBVcccDNA可作为HBV宫内感染的重要指标,同时也能作为评价母婴阻断疗效的良好指标,其检测具有较高的临床价值,值得推广应用.%Objective To analyze the value of HBVcccDNA in the diagnosis of hepatitis B virus (HBV) intrauterine infection, and to evaluate the effects of lamivudine in the blocking of HBV intrauterine infection. Methods Sixty pregnant women in our clinic and hospital from May 2011 to June 2012 were randomly divided into the study group (n=32) and the control group (n=28). Blood samples were collected at 28 weeks gestation, prenatal and postnatal 24 h, and postpartum 3 months. HBVDNA, HBVcccDNA were measured by PCR. The results of HBVcccDNA quantitative detection and the incidence of intrauterine infection were compared between the two groups. Results In the study group, the level of HBV-DNA and HBVcccDNA at 28 weeks gestation in the study group showed no statistically significant difference with those in the control group (P>0.05). The levels of HBV-DNA and HBVcccDNA at prenatal and postnatal 24 h, postpartum 3 months and the level of HBVcccDNA in the placental tissue of pregnant women in prenatal intrapartum in the study group showed statistically significant difference with those in the control group (P<0.05). The incidence of intrauterine infection in the study group was significantly lower than that in the control group (P<0.05). Conclusion The detection of HBVcccDNA can be used as an important indicator of HBV intrauterine infection and also a good indicator to evaluate the efficacy of PMTCT, which has high clinical value and should be widely applied.